It was reported previously that malignant human tumors, like glioma and medulloblastoma, express high-density interleukin (IL-4) receptor mRNA and protein. Because IL-4 receptors (R) are sensitive targets for targeted therapeutics, knowledge of the expression of these receptors in other central nervous system tumors is of great interest. In this study, the authors examined the expression and subunit composition of IL-4R complex in primary human meningiomas.
Reverse transcription-polymerase chain reaction (RT-PCR) analysis for IL-13Rα1, IL-4Rα and IL-2Rγc was performed on total RNA extracted from 35 meningiomas and a normal human brain tissue sample. Results were confirmed in nine randomly selected tumors by quantitative real-time PCR and in situ immunofluorescence assay.
Transcripts for the IL-4Rα and IL-13Rα1 chains were overexpressed in meningiomas compared with normal brain tissue. The levels of IL-4Rα mRNA appeared to be higher compared with the levels of IL-13Rα1 mRNA. The results also showed that tumors with higher disease grade tended to have increased mRNA expression for the IL-4Rα chain. This IL-4Rα mRNA overexpression appeared to be more frequent in younger patients (age < 37 years). The transcripts for IL-2Rγc chain were not detected in any of the tumor samples or in normal brain tissue. Quantitative real-time PCR confirmed the results of the RT-PCR analysis. Meningiomas also demonstrated a bright immunofluorescent staining for the IL-4Rα and IL-13Rα1 chains but no staining for IL-2Rγc.
Expression of the IL-4Rα and IL-13Rα1 chains and absence of IL-2γc expression established that meningiomas expressed type II IL-4Rs. These receptors may serve as a target for cytotoxin/immunotoxin therapy in patients with meningioma who are not amenable to surgical resection or for recurrent tumors. Cancer 2005. © 2005 American Cancer Society.